Ornithine decarboxylase activity in prostate cancer

Abstract

Summary. Prostate cancer (PCa), the most common solid malignant neoplasm in men, is characterized using the Gleason score and diagnosed using prostate-specific antigen (PSA) biomarker. However, Gleason score and PSA-based diagnostics are not universal and have significant limitations. It is supposed that the ornithine decarboxylase activity (AODC) could be a suitable auxiliary biomarker for the PCa diagnosis or monitoring the therapeutic efficacy. Aim: To assess the relation between AODC in PCa tissues and the level of serum PSA with the Gleason score (GS) and the clinical stage. Materials and Methods: 29 patients (48 to 79 years old) with prostate adenocarcinoma of different GS (6 to 10) and clinical stage (T1 to T4) were enrolled in the study. The AODC was analyzed in the PCa tissues by the modified spectrophotometric assay. Results: The patients with PCa were distributed into two groups: with low AODC < 0.3 and high AODC > 0.45. In group with AODC < 0.3, the highest value of AODC was recorded in patients with the lowest GS (= 6), while in group with AODC > 0.45, the highest value of AODC was recorded in the patients with the highest GS (= 9–10). Furthermore, in group with AODC > 0.45, the highest value of AODC was registered in the patients with T1 or T4 stage. The highest levels of serum PSA were detected in T3–T4 cases and in cases with the highest GS. Conclusion: The patterns of AODC and serum PSA can be used as supplementary indices useful for monitoring PCa course.

Cytotoxic Effects of Rheum khorasanicum Extract on MCF-7 Human Breast Cancer Cell Line and ODC1 Gene Expression

“…Increased levels of the ODC enzyme have an essential effect on the metabolism of polyamines in cancer cells. Polyamines are ubiquitous molecules in eukaryotic cells and play a key role in cell growth, survival, and differentiation (7,22). Accordingly, identifying them and their synthesis pathways would be crucial in understanding cell biology and, ultimately, a suitable target for controlling cell growth.…”

“…The molecular dysregulation of the ODC1 gene could alter its expression patterns and leads to overexpression in cancer cells. Studies have revealed that ODC downregulation and activity decline could be associated with the reduced growth of cancer cells (6,7). The current chemical drugs against cancer cells are primarily ineffective and associated with several unwanted side effects.…”

A Review of Prostate Organogenesis and a Role for iPSC-Derived Prostate Organoids to Study Prostate Development and Disease

“…Other factors involved in prostate development and disease include AKT [ 92 ], BMP1RA [ 93 ], CTNNB1 [ 94 , 95 ], E-Cadherin [ 96 ], EFNB1 [ 97 ], GLI1 [ 98 ], GLI2 [ 99 ], HSP27 [ 100 ], HSPE [ 101 ], IL-6 [ 102 ], IL1R1 [ 103 ], LGR4 [ 104 ], MMP2 [ 105 ], MYC [ 106 ], ODC1 [ 107 ], PAX2 [ 108 ], p53 [ 109 ], P63 [ 110 ], PTN [ 111 ], PTEN [ 112 ], R-spondin3 [ 113 ], SFRP1 [ 114 ], SOX9 [ 115 ], SULF1 [ 116 ], TGFB [ 117 ], TMPRSS2 [ 118 ], VEGF [ 119 ] and WIF1 [ 120 ].…”

Preventing Cancer by Inhibiting Ornithine Decarboxylase: A Comparative Perspective on Synthetic vs. Natural Drugs

“…The ODC (Ornithine Decarboxylase enzyme) plays a significant role as a transcriptional target of the MYC oncogene in between polyamine metabolism and oncogene for both regular and cancer cells [8,10–11,18] . Many tumor cell activity which leads to developing cancer was observed due to ODC activation with higher polyamine activities such as Lung cancer, [19] Prostrate cancer [20–21] Neuroblastoma, [22] Breast cancer [23–24] Esophageal cancer, [25] Pancreatic cancer, [26] Colorectal cancer [24,27] Endometrial cancer [28] etc.…”